Article Type
Video
Changed
Fri, 01/04/2019 - 11:59
Display Headline
ASCO 2012: Radium-223 and Prostate Cancer Survival

Dr. Chris Parker of Royal Marsden Hospital in London discusses the ALSYMPCA trial of radium-223 (Alpharadin), the first agent to improve prostate cancer survival by targeting bone metastases.

Meeting/Event
2012 ASCO Annual Meeting
Author and Disclosure Information

Publications
Oncology Practice
MDedge Hematology and Oncology
Topics
Genitourinary Cancer
Legacy Keywords
Dr. Chris Parker, ALSYMPCA trial, radium-223, prostate cancer survival
Author and Disclosure Information

Author and Disclosure Information

Meeting/Event
2012 ASCO Annual Meeting
Meeting/Event
2012 ASCO Annual Meeting

Dr. Chris Parker of Royal Marsden Hospital in London discusses the ALSYMPCA trial of radium-223 (Alpharadin), the first agent to improve prostate cancer survival by targeting bone metastases.

Dr. Chris Parker of Royal Marsden Hospital in London discusses the ALSYMPCA trial of radium-223 (Alpharadin), the first agent to improve prostate cancer survival by targeting bone metastases.

Publications
Oncology Practice
MDedge Hematology and Oncology
Publications
Oncology Practice
MDedge Hematology and Oncology
Topics
Genitourinary Cancer
Article Type
Video
Display Headline
ASCO 2012: Radium-223 and Prostate Cancer Survival
Display Headline
ASCO 2012: Radium-223 and Prostate Cancer Survival
Legacy Keywords
Dr. Chris Parker, ALSYMPCA trial, radium-223, prostate cancer survival
Legacy Keywords
Dr. Chris Parker, ALSYMPCA trial, radium-223, prostate cancer survival
Article Source

PURLs Copyright

Inside the Article